EA201991399A1 - Аминотриазолопиридиновые соединения и их применение в лечении рака - Google Patents

Аминотриазолопиридиновые соединения и их применение в лечении рака

Info

Publication number
EA201991399A1
EA201991399A1 EA201991399A EA201991399A EA201991399A1 EA 201991399 A1 EA201991399 A1 EA 201991399A1 EA 201991399 A EA201991399 A EA 201991399A EA 201991399 A EA201991399 A EA 201991399A EA 201991399 A1 EA201991399 A1 EA 201991399A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
salts
treatment
cancer
aminotriazolopyridine
Prior art date
Application number
EA201991399A
Other languages
English (en)
Other versions
EA037745B1 (ru
Inventor
Морис Реймонд Верскойл Финлей
Фредерик Вулф Голдберг
Аттила Куан Тсуэй Тинг
Original Assignee
Астразенека Аб
Кэнсер Рисерч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб, Кэнсер Рисерч Текнолоджи Лимитед filed Critical Астразенека Аб
Publication of EA201991399A1 publication Critical patent/EA201991399A1/ru
Publication of EA037745B1 publication Critical patent/EA037745B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Описание в общем относится к соединениям формулы (I)и их фармацевтически приемлемым солям, где Rи Rимеют любое из значений, определенных в данном документе. Описание также относится к применению таких соединений и их солей для лечения или предупреждения заболевания, опосредованного DNA-PK, в том числе рака. Описание дополнительно относится к фармацевтическим композициям, содержащим такие соединения и соли; наборам, содержащим такие соединения и соли; способам получения таких соединений и солей; промежуточным соединениям, пригодным в получении таких соединений и солей; и к способам лечения заболевания, опосредованного DNA-PK, в том числе рака, с применением таких соединений и солей.
EA201991399A 2016-12-20 2017-12-19 Аминотриазолопиридиновые соединения и их применение в лечении рака EA037745B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436619P 2016-12-20 2016-12-20
PCT/EP2017/083625 WO2018114999A1 (en) 2016-12-20 2017-12-19 Amino-triazolopyridine compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
EA201991399A1 true EA201991399A1 (ru) 2020-01-22
EA037745B1 EA037745B1 (ru) 2021-05-18

Family

ID=60937727

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991399A EA037745B1 (ru) 2016-12-20 2017-12-19 Аминотриазолопиридиновые соединения и их применение в лечении рака

Country Status (38)

Country Link
US (4) US10407446B2 (ru)
EP (1) EP3558997B1 (ru)
JP (1) JP6883653B2 (ru)
KR (1) KR102220971B1 (ru)
CN (1) CN110177791B (ru)
AR (1) AR110400A1 (ru)
AU (1) AU2017384388B2 (ru)
BR (1) BR112019012217B1 (ru)
CA (1) CA3046339C (ru)
CL (1) CL2019001714A1 (ru)
CO (1) CO2019007810A2 (ru)
CR (1) CR20190301A (ru)
CY (1) CY1124239T1 (ru)
DK (1) DK3558997T3 (ru)
DO (1) DOP2019000168A (ru)
EA (1) EA037745B1 (ru)
EC (1) ECSP19044159A (ru)
ES (1) ES2867274T3 (ru)
HR (1) HRP20210548T1 (ru)
HU (1) HUE054548T2 (ru)
IL (1) IL267158B (ru)
JO (1) JOP20190151B1 (ru)
LT (1) LT3558997T (ru)
MA (1) MA47079B1 (ru)
MX (1) MX2019007189A (ru)
MY (1) MY183036A (ru)
NI (1) NI201900062A (ru)
NZ (1) NZ755222A (ru)
PE (1) PE20191474A1 (ru)
PH (1) PH12019501350A1 (ru)
PL (1) PL3558997T3 (ru)
PT (1) PT3558997T (ru)
RS (1) RS61701B1 (ru)
SI (1) SI3558997T1 (ru)
TW (1) TWI776835B (ru)
UA (1) UA123032C2 (ru)
WO (1) WO2018114999A1 (ru)
ZA (1) ZA201904695B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191474A1 (es) 2016-12-20 2019-10-16 Astrazeneca Ab Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
WO2020186211A1 (en) * 2019-03-13 2020-09-17 The Uab Research Foundation Methods and compositions for treating polyoma virus infection
TW202110849A (zh) * 2019-05-27 2021-03-16 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑
CA3142521A1 (en) 2019-06-17 2020-12-24 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
EP4063371A1 (en) * 2019-11-22 2022-09-28 Medshine Discovery Inc. Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors
JP7383818B2 (ja) * 2019-11-25 2023-11-20 ザイ ラボ （シャンハイ） カンパニー、リミテッド． Ｄｎａ－ｐｋ阻害剤としてのピリミドイミダゾル系化合物
IL293293A (en) 2019-11-26 2022-07-01 Primmune Therapeutics Inc tlr7 agonists
US20220402920A1 (en) 2019-12-31 2022-12-22 Chengdu Baiyu Pharmaceutical Co., Ltd. Purine derivative and medical use thereof
WO2021136462A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
WO2021136461A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
CN113493471A (zh) * 2020-04-03 2021-10-12 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂
CN113549092B (zh) * 2020-04-23 2022-10-18 山东轩竹医药科技有限公司 三并环类激酶抑制剂
IL297550A (en) 2020-04-28 2022-12-01 Intellia Therapeutics Inc Methods for in vitro cell delivery
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
WO2022017368A1 (zh) * 2020-07-20 2022-01-27 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
US20220040173A1 (en) * 2020-08-04 2022-02-10 Astrazeneca Ab Methods of delaying pain progression and treating prostate cancer
CN114249753A (zh) * 2020-09-22 2022-03-29 山东轩竹医药科技有限公司 三唑并吡啶类激酶抑制剂
CN114634522A (zh) * 2020-12-15 2022-06-17 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
US20220228142A1 (en) 2020-12-17 2022-07-21 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
WO2022135360A1 (zh) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
TW202229281A (zh) * 2020-12-24 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮類化合物、其製備方法及其在醫藥上的應用
CN116917288A (zh) * 2021-03-22 2023-10-20 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
BR112023021429A2 (pt) 2021-04-17 2024-01-23 Intellia Therapeutics Inc Inibidores de proteína quinase dependente de dna e composições e usos dos mesmos
WO2022242658A1 (zh) * 2021-05-19 2022-11-24 南京明德新药研发有限公司 杂环取代的嘌呤酮衍生物的盐型及晶型
WO2023274310A1 (zh) * 2021-06-29 2023-01-05 成都百裕制药股份有限公司 嘌呤衍生物的晶型及其药物组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
JP4895811B2 (ja) 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
AU2005214258A1 (en) 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compound
US7947695B2 (en) * 2005-01-14 2011-05-24 Janssen Pharmaceutica Nv 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20090023723A1 (en) 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
AU2006301435A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as Syk inhibitors
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
US7919490B2 (en) * 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EP2078016B1 (en) 2006-10-19 2012-02-01 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US8436004B2 (en) 2007-06-15 2013-05-07 Msd K.K. Bicycloaniline derivative
NZ584138A (en) 2007-08-23 2011-10-28 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
US9555033B2 (en) 2010-02-03 2017-01-31 Signal Pharmaceuticals, Llc Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
CA2831680C (en) 2011-04-21 2020-04-21 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
UY34032A (es) 2011-04-21 2012-11-30 Origenis Gmbh Nuevos inhibidores de quinasa
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
JP6121658B2 (ja) 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
EP3659599B1 (en) 2011-10-19 2022-12-21 Signal Pharmaceuticals, LLC 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for use in the treatment of glioblastoma multiforme
EP2825168B1 (en) * 2012-03-15 2018-05-09 Signal Pharmaceuticals, LLC Treatment of cancer with tor kinase inhibitors
CN102675897B (zh) 2012-05-18 2015-04-29 陕西师范大学 硫脲/脲芳胺染料及其制备方法和应用
CN103864792B (zh) 2012-12-12 2017-01-18 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮并环类化合物
US20160008356A1 (en) 2013-02-28 2016-01-14 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
NO2714752T3 (ru) 2014-05-08 2018-04-21
PE20191474A1 (es) 2016-12-20 2019-10-16 Astrazeneca Ab Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer

Also Published As

Publication number Publication date
PH12019501350A1 (en) 2020-01-20
SI3558997T1 (sl) 2021-07-30
BR112019012217B1 (pt) 2021-08-10
US20240124492A1 (en) 2024-04-18
KR20190092573A (ko) 2019-08-07
AR110400A1 (es) 2019-03-27
CA3046339C (en) 2022-02-22
MA47079A (fr) 2019-10-30
PT3558997T (pt) 2021-04-13
MX2019007189A (es) 2019-10-09
BR112019012217A2 (pt) 2019-11-12
JP6883653B2 (ja) 2021-06-09
UA123032C2 (uk) 2021-02-03
CO2019007810A2 (es) 2019-10-09
IL267158B (en) 2020-10-29
KR102220971B1 (ko) 2021-02-25
AU2017384388B2 (en) 2020-09-17
ECSP19044159A (es) 2019-06-30
DK3558997T3 (da) 2021-04-19
RS61701B1 (sr) 2021-05-31
JOP20190151B1 (ar) 2023-09-17
US10407446B2 (en) 2019-09-10
NI201900062A (es) 2020-07-22
ZA201904695B (en) 2021-05-26
LT3558997T (lt) 2021-04-26
EP3558997B1 (en) 2021-01-27
US11136340B2 (en) 2021-10-05
TWI776835B (zh) 2022-09-11
IL267158A (en) 2019-08-29
CA3046339A1 (en) 2018-06-28
CN110177791A (zh) 2019-08-27
CR20190301A (es) 2019-09-04
MA47079B1 (fr) 2021-05-31
TW201837045A (zh) 2018-10-16
NZ755222A (en) 2022-07-01
US20180194782A1 (en) 2018-07-12
US20220041625A1 (en) 2022-02-10
CY1124239T1 (el) 2022-07-22
AU2017384388A1 (en) 2019-07-25
CN110177791B (zh) 2022-07-12
ES2867274T3 (es) 2021-10-20
CL2019001714A1 (es) 2019-09-06
MY183036A (en) 2021-02-08
DOP2019000168A (es) 2019-07-15
HUE054548T2 (hu) 2021-09-28
HRP20210548T1 (hr) 2021-05-14
US20200048281A1 (en) 2020-02-13
WO2018114999A1 (en) 2018-06-28
JP2020504107A (ja) 2020-02-06
EA037745B1 (ru) 2021-05-18
PE20191474A1 (es) 2019-10-16
JOP20190151A1 (ar) 2019-06-20
US11746118B2 (en) 2023-09-05
EP3558997A1 (en) 2019-10-30
PL3558997T3 (pl) 2021-07-19

Similar Documents

Publication Publication Date Title
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
EA202190006A1 (ru) Пуриноновые соединения и их применение при лечении рака
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA202092600A1 (ru) Тетрациклические гетероарильные соединения
EA201892527A1 (ru) Ингибиторы энхансера гомолога 2 белка zeste
EA202092344A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201990074A1 (ru) Гетероциклические соединения как иммуномодуляторы